Actively Recruiting
PDO Based Drug Sensitive Test in R/M SGC
Led by Huashan Hospital · Updated on 2025-09-03
40
Participants Needed
2
Research Sites
192 weeks
Total Duration
On this page
Sponsors
H
Huashan Hospital
Lead Sponsor
S
Shanghai Cancer Hospital, China
Collaborating Sponsor
AI-Summary
What this Trial Is About
To evaluate the consistency of drug efficacy between the clinical systemic treatment and drug sensitive test based on patient-derived organoid in R/M SGC patients, using a prospective and multicenter observational study to increase the generalizability and reliability of research conclusion.
CONDITIONS
Official Title
PDO Based Drug Sensitive Test in R/M SGC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically confirmed recurrent or metastatic salivary gland cancer patients
- Tumor tissue available for organoid culture
- ECOG performance status score between 0 and 2
- Life expectancy greater than 3 months
- Normal major organ function and able to tolerate chemotherapy, targeted therapy, or immunotherapy, including hematology, liver, kidney, and coagulation function within specified limits
- Able to understand and sign informed consent and willing to participate in follow-up
You will not qualify if you...
- Metastatic tumors in the head and neck region other than salivary gland cancer, including sarcoma, squamous cell carcinoma, and nasopharyngeal carcinoma
- Known allergy to study drugs or their components, or history of severe allergic reaction to monoclonal antibodies
- Pregnant or breastfeeding women, or women of childbearing age not using effective contraception, or male patients with partners of childbearing age not using contraception during and after study
- Severe uncontrolled liver, kidney, respiratory, hematopoietic, or endocrine diseases
- Infection with HIV, active hepatitis B or C, or uncontrolled infectious diseases
- Major cardiovascular events or serious heart conditions within 6 months before enrollment
- History of mental illness, psychiatric drug abuse, or drug addiction
- Unable to provide informed consent or sufficient tumor tissue for study
- Other serious physical or mental conditions or lab abnormalities that increase risk or interfere with study participation as judged by researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China, 200040
Active, Not Recruiting
2
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China, 200040
Actively Recruiting
Research Team
L
Lai-ping Zhong, MD, PhD
CONTACT
T
Tong-chao Zhao, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here